Replimune Group, Inc.
US ˙ NasdaqGS ˙ US76029N1063

Introduction

This page provides a comprehensive analysis of the known insider trading history of Sushil Patel. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Sushil Patel has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RVMD / Revolution Medicines, Inc. Director 23,090
US:REPL / Replimune Group, Inc. Chief Executive Officer, Director 343,576
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Sushil Patel. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases REPL / Replimune Group, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in REPL / Replimune Group, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

REPL / Replimune Group, Inc. Insider Trades
Insider Sales REPL / Replimune Group, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in REPL / Replimune Group, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-05-20 REPL Patel Sushil 25,105 8.0600 25,105 8.0600 202,346 63 2.8050 -131,926 -65.20
2024-05-16 REPL Patel Sushil 20,194 6.4700 20,194 6.4700 130,655
2023-05-16 REPL Patel Sushil 15,575 18.0500 15,575 18.0500 281,129
2022-05-16 REPL Patel Sushil 10,687 14.5900 10,687 14.5900 155,923

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

REPL / Replimune Group, Inc. Insider Trades
Insider Purchases RVMD / Revolution Medicines, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in REPL / Replimune Group, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RVMD / Revolution Medicines, Inc. Insider Trades
Insider Sales RVMD / Revolution Medicines, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in REPL / Replimune Group, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RVMD / Revolution Medicines, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Sushil Patel as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-30 2025-06-26 4 RVMD Revolution Medicines, Inc.
Common Stock
A - Award 3,142 23,090 15.75
2025-05-22 2025-05-20 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -25,105 343,576 -6.81 8.06 -202,346 2,769,223
2025-04-03 2025-04-01 4 REPL Replimune Group, Inc.
Common Stock
A - Award 166,667 368,681 82.50
2024-12-18 2024-12-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -10,000 202,014 -4.72 12.42 -124,200 2,509,014
2024-11-04 2024-10-31 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -5,000 19,948 -20.04 54.14 -270,714 1,080,043
2024-11-04 2024-10-31 4 RVMD Revolution Medicines, Inc.
Common Stock
M - Exercise X 5,000 24,948 25.07 24.84 124,200 619,708
2024-07-10 2024-07-09 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -2,155 19,948 -9.75 44.00 -94,820 877,712
2024-07-10 2024-07-09 4 RVMD Revolution Medicines, Inc.
Common Stock
M - Exercise X 2,155 22,103 10.80 16.80 36,204 371,330
2024-06-28 2024-06-20 4/A RVMD Revolution Medicines, Inc.
Common Stock
A - Award 4,248 19,948 27.06
2024-06-24 2024-06-20 4 RVMD Revolution Medicines, Inc.
Common Stock
A - Award 4,800 20,500 30.57
2024-05-20 2024-05-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -20,194 212,014 -8.70 6.47 -130,655 1,371,731
2024-04-12 2024-04-10 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -2,155 15,700 -12.07 37.00 -79,735 580,900
2024-04-12 2024-04-10 4 RVMD Revolution Medicines, Inc.
Common Stock
M - Exercise X 2,155 17,855 13.73 16.80 36,204 299,964
2024-04-03 2024-04-01 4 REPL Replimune Group, Inc.
Common Stock
A - Award 83,335 232,208 55.98
2023-06-15 2023-06-13 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -553 148,873 -0.37 23.44 -12,962 3,489,583
2023-06-15 2023-06-13 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -5,145 149,426 -3.33 24.11 -124,046 3,602,661
2023-06-12 2023-06-08 4 RVMD Revolution Medicines, Inc.
Common Stock
A - Award 5,200 15,700 49.52
2023-05-18 2023-05-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -15,575 154,571 -9.15 18.05 -281,129 2,790,007
2023-04-04 2023-04-01 4 REPL Replimune Group, Inc.
Common Stock
A - Award 40,000 170,146 30.73
2022-06-17 2022-06-16 4 RVMD Revolution Medicines, Inc.
Common Stock
A - Award 10,500 10,500
2022-05-18 2022-05-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -10,687 130,146 -7.59 14.59 -155,923 1,898,830
2022-04-05 2022-04-01 4 REPL Replimune Group, Inc.
Employee Stock Option (right to buy)
A - Award 78,750 78,750
2022-04-05 2022-04-01 4 REPL Replimune Group, Inc.
Common Stock
A - Award 52,500 140,833 59.43
2021-05-05 2021-05-03 4 REPL Replimune Group, Inc.
Employee Stock Option (right to buy)
A - Award 125,000 125,000
2021-05-05 2021-05-03 4 REPL Replimune Group, Inc.
Common Stock
A - Award 88,333 88,333
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)